First Mainland China Patient Dosed in Pivotal Phase 2 Trial Testing MOR202 in Multiple Myeloma
I-Mab Biopharma has dosed the first patient in…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Pivotal DREAMM-2 Trial Supports Belantamab Mafodotin’s Use for Heavily-treated Multiple Myeloma
Treatment with belantamab mafodotin, GlaxoSmithKline’s…
Myeloma Patients in Phase 1 Trial Show High Response Rates with REGN5458 Treatment
Treatment with Regeneron Pharmaceuticals‘…
PNK-007 Treatment After Stem Cell Transplant Leads to Good Response Rates in Multiple Myeloma Patients, Early Trial Data Show
A single infusion of Celularity‘s PNK-007 — an…
Analysis Group Announces Collaboration to Improve Blood Disease Research and Treatment in China
Analysis Group is collaborating with China’s Institute…
Top 10 Multiple Myeloma Stories of 2019
Myeloma Research News brought you daily…
